Skip to content

Ascentage Pharma

US · AAPG #3045 by market cap Listed 2025
11.97 -0.47 -3.78%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 12.07 -2.97%
After-hours 11.97 0.00%
20.9011.9711.972026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on AAPG?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -46.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 91.5% Better than 97%
Operating margin -208.6% Better than 5%
Net margin -216.5% Better than 5%
Return on equity -156.5% Better than 4%
Return on invested capital -48.3% Better than 6%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -29.6% Better than 18%
6-month return -43.0% Better than 10%
12-month return (ex latest month) -51.3% Better than 3%
Distance below 52-week high 63.8% Better than 9%
Financial Health D

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 1.8x Better than 51%
Debt to assets 49.9% Better than 15%
Interest coverage -21.9x Better than 9%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 250.9% Better than 96%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -18.13%
1M -24.81%
3M -30.89%
6M -39.48%
YTD -54.38%
1Y -61.73%

Key statistics

Price & volume

Prev close
12.44
Open
12.26
Day range
11.97 - 12.26
Avg price
12.20
Volume
5.04K
Turnover
61.48K
Amplitude
2.33%
52-week range
11.97 - 33.09

Valuation

P/E
-5.99
P/E (TTM)
-5.07
P/B
13.39
EPS
-2.00
Net profit
-186.50M
Net assets
83.49M

Share structure

Market cap
1.12B
Float cap
868.55M
Shares out
93.39M
Float shares
72.56M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2025-01-24
52-week range 0% of range
11.97 33.09

63.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+17.54K net over the window

Short interest

Shares short
9.13K
As of
2026-10-30

Frequently asked questions

What is the current stock price of Ascentage Pharma (AAPG)?

Ascentage Pharma last traded at 11.97. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Ascentage Pharma's market cap?

About 1.12B.

What is the P/E ratio of Ascentage Pharma?

The trailing twelve-month P/E is -5.07. The Valuation tab shows it against the stock's own five-year range.

Does Ascentage Pharma pay a dividend?

Ascentage Pharma does not currently pay a regular dividend.

Is Ascentage Pharma a buy according to analysts?

The consensus of 7 analysts is a Buy rating, with an average 12-month price target of 42.00, which implies 250.9% upside from the current price. This is not investment advice.

What is Ascentage Pharma's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Ascentage Pharma a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.

Ascentage Pharma discussion 0 comments

Add a comment